

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**PATENT TRIAL AND APPEAL BOARD**

---

ADAMIS PHARMACEUTICALS CORPORATION  
Petitioner

v.

BELCHER PHARMACEUTICALS, LLC  
Patent Owner

---

CASE: IPR2019-01021  
U.S. PATENT NO. 9,283,197

---

**DECLARATION OF JAMES KIPP, PH.D. IN SUPPORT OF PETITION  
FOR *INTER PARTES* REVIEW OF U.S. PATENT 9,283,197**

## CONTENTS

I.	INTRODUCTION .....	1
II.	QUALIFICATIONS AND BACKGROUND .....	3
III.	OVERVIEW OF THE TECHNOLOGY .....	7
	A. Epinephrine Compound.....	7
	B. Epinephrine Injections.....	8
	C. Racemization and Oxidation Processes .....	10
	D. Adrenalone and Other Impurities.....	12
IV.	THE '197 PATENT .....	14
V.	LEVEL OF SKILL IN THE ART .....	16
VI.	CLAIM CONSTRUCTION .....	18
VII.	SUMMARY OF OPINIONS.....	20
VIII.	OVERVIEW OF PRIOR ART .....	24
	A. Stepensky.....	24
	B. USP.....	29
	C. Gupta .....	31
	D. Bruss .....	33
	E. Fyllingen.....	35
	F. Zeleznick .....	36
	G. Szulczewski .....	37
IX.	DETAILED ANALYSIS.....	39
	A. Prior Art Showing Motivation to Minimize Degradation in Sterile Liquid Injectable Pharmaceutical Formulations of l-Epinephrine .....	40

B.	Prior Art Showing How to Manufacture the Said Liquid Pharmaceutical Formulation .....	41
1.	Said Liquid Pharmaceutical Formulation Having a pH Between 2.8 and 3.3 .....	42
2.	Said Injectable Liquid Pharmaceutical Formulation Compounded in an Aqueous Solution as 1.0 to 1.06 mg/mL L-Epinephrine, and Further Including a Tonicity Agent. ....	43
3.	Said Liquid Pharmaceutical Formulation Including no More Than About 6% D-Epinephrine and no More Than About 0.5% Adrenalone at Release .....	45
4.	Said Liquid Pharmaceutical Formulation Including no More Than About 12% D-Epinephrine and no More Than About 0.5% Adrenalone Over a Shelf-Life of at Least 12 Months .....	46
5.	Said Liquid Pharmaceutical Formulation Having a Concentration of 1 mg per mL L-Epinephrine .....	49
<b>X.</b>	<b>COMBINATIONS</b> .....	49
C.	Stepensky and USP .....	50
D.	Stepensky and Gupta.....	52
E.	Bruss and USP and Fyllingen.....	53
F.	Gupta and Fyllingen and Zeleznick .....	54
G.	Szulczewski and Fyllingen.....	55
H.	Szulczewski and Fyllingen and Gupta .....	56
<b>XI.</b>	<b>SECONDARY CONSIDERATIONS</b> .....	56

I, James Kipp, Ph.D., do hereby declare and say:

**I. INTRODUCTION**

1. I am over the age of twenty-one (21) and competent to make this declaration. I am also qualified to give testimony under oath. The facts and opinions listed below are within my personal knowledge.

2. I have been engaged in this matter to provide my independent analysis of certain issues I understand arise in connection with the *Inter Partes* Review of U.S. Patent No. 9,283,197 (which I refer to as the ‘197 Patent). (Ex. 1001). I am being compensated for my time in connection with this IPR at my standard consulting rates. I have received no compensation for this declaration beyond my normal hourly rate for time spent on this matter, and I will not receive any added compensation based on the outcome of any proceeding related to the ‘197 Patent.

3. I have been asked to review certain documents, including the ‘197 Patent (Ex. 1001), and to provide my opinions on how those of skill in the art (as defined herein) would understand those documents. For purposes of this declaration, the documents I was asked to review include:

Ex. 1001	U.S. Patent No. 9,283,197 (“‘197 Patent”)
Ex. 1004	File History of U.S. Patent No. 9,283,197
Ex. 1005	Stepensky, D., <i>Long-Term Stability Study of L-Adrenaline Injections: Kinetics of Sulfonation and Racemization Pathways of Drug Degradation</i> , Journal of Pharmaceutical Sciences, Vol. 93 No. 4, published in April 2004 (“Stepensky”)

Ex. 1006	U.S. Patent Application Publication No. 2008/0269347 to Bruss et al. (“ <i>Bruss</i> ”)
Ex. 1007	Fyllingen, G., <i>Racemisation and oxidation in adrenaline injections</i> , Acta Pharm. Nord. 2(5) 1990 (“ <i>Fyllingen</i> ”)
Ex. 1008	Vidal-Ollivier, E., <i>Assay for epinephrine and its impurities using reversed-phase high-performance liquid chromatography</i> , Journal of Chromatography 1987 (“ <i>Vidal</i> ”)
Ex. 1009	Kerddonfak, S., <i>The Stability and Sterility of Epinephrine Prefilled Syringe</i> , Asian Pacific Journal of Allergy and Immunology, 2010 (“ <i>Kerddonfak</i> ”)
Ex. 1010	U.S. Patent No. 5,002,973 to Zeleznick et al. (“ <i>Zeleznick</i> ”)
Ex. 1011	International Patent Publication No. WO 2014/127015 to Gupta et al. (“ <i>Gupta</i> ”)
Ex. 1012	Connors, K.A. <i>Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists</i> , 2nd Edition, published in 1986 (“ <i>Connors</i> ”)
Ex. 1013	2004 United States Pharmacopeia Monograph for Epinephrine
Ex. 1014	2009 United States Pharmacopeia Monograph for Epinephrine (“ <i>USP</i> ”)
Ex. 1015	2014 United States Pharmacopeia Monograph for Epinephrine
Ex. 1016	Analytical Profiles of Drug Substances, 7, Epinephrine by Dale H. Szulczewski et al., published in 1978 (“ <i>Szulczewski</i> ”)
Ex. 1017	Moed H.D. et al., <i>Synthesis of beta-phenyl-ethylamine derivatives III Bronchodilators</i> , Rec. Trav. Chim. 74, 1955 (“ <i>Moed</i> ”)
Ex. 1018	IMS Product Information
Ex. 1019	Claim Construction Order in Case No. 17-775-LPS, <i>Belcher Pharmaceuticals, LLC v. Hospira, Inc</i>
Ex. 1020	Belcher Initial Infringement Contentions in Case No. 8:18-cv-02379-WFJ-AAS, <i>Adamis Pharmaceuticals Corp. v. Belcher Pharmaceuticals, LLC</i>
Ex. 1022	Goodman, L.S., <i>The Pharmacological Basis of Therapeutics</i> , 5 <sup>th</sup> Edition, (“ <i>Goodman</i> ”) published in 1975
Ex. 1023	Belcher Expert Report in Case No. 17-775-LPS

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.